Bayer and Amgen's Onyx subsidiary announce an oncology drug failed a Phase-III trial goal among liver cancer patients.
The drugmaker announced Tuesday that it will pursue a Phase-III Yervoy-nivolumab study.
A pilot program including mailed colon-cancer screening tests increased use of the tests among under-served patients.
Adding Avastin to chemotherapy added four months of survival, data show.
The drugmaker's new vaccine has more brawn, but vaccination rates among boys and girls remain low.
The drugmaker was scant on details, but Phase-III ramucirumab results among non-small cell lung cancer patients showed increased overall and progression-free survival vs. placebo.
The drugmaker's purchase of private biotech CoStim Pharmaceuticals comes with a host of experimental immuno-oncology agents.
The fast-tracked drug netted another indication today, this one for a form of leukemia. Lower dosage of the drug for that indication shrinks the price compared to lymphoma.
Hitting a vaccination rate of 80% of girls would mean 53,000 fewer cases of cervical cancer.
A court in India ruled biosimilar drug makers will not be able to cite the drug's name, efficacy or safety profile in its marketing.
The company expects to return to growth in 2015 as it focuses on immunotherapy collaborations.
The proposed solutions include education, access and low-cost interventions.
The company said in a statement that it is talking with the FDA about next steps. Data on overall survival—a key metric for how oncologists view new cancer meds—remains under wraps.
The two will explore cancer-attacking nanobodies.
New research finds overlap with some forms of breast, lung, and head & neck cancers, as well as 32 recurring genetic mutations.
The drug maker is kicking in $5 million—or 20% of funding—for the research "dream team," which is part of an alliance between Stand Up and the American Cancer Society.
A clinical trial shows that using Xtandi before chemotherapy—Zytiga's indication—improves progression-free survival.
The company said it may use Phase II data of a breast cancer drug for FDA review, part of an earnings presentation that also included its perspective on what a pre-2017 breakup would take.
Friday's no-nivolumab news event disappointed some, but analysts generally rooted for BMS, which saw year-end sales fall 7%, because of anticipated immuno-oncology success.
Merck and Celgene are exploring a combination that could solidify their immuno-oncology footholds.
It was granted based on data among patients with BRAF V600E mutation-positive non-small lung cancer who have undergone chemo.
Herve Hoppenot changed jobs overnight.
The FDA said it's OK to use Mekinist and Tafinlar for unresectable metastatic melanoma or metastatic melanoma with the BRAF V600 or V600K mutation.
The new deals seek out new strategies to address an expansive category.
Cambridge, MA-based Epizyme claimed $29 million in milestone payments from the two drugmakers.
The company releases 2014 guidance Tuesday, but signals from the previous 12 months indicate the Indiana drugmaker is determined to hit its $20-billion earnings target, patent losses be damned.
Our year-end list captures the 10 that sparked heaviest interest.
The $2.9 billion deal means Bayer owns prostate cancer drug Xofigo in full.
The trio will focus on using immune systems to attack cancer.
Goldman Sachs's Jami Rubin says AbbVie's pipeline assets make it a stealth competitor.